A large biotechnology company wanted to supplement their existing portfolio of clinical stage assets. IMIHGOM was engaged to perform a landscape analysis across Europe, to identify high potential late-stage clinical assets in oncology.
As a virtual extension of our client’s innovation team, we support our clients with their licensing transactions, from sourcing to closing. We take a flexible approach and tailor our services to the client’s internal capabilities. IMIHGOM aims to achieve our client’s goals faster, better and cheaper than they could do it themselves
As part of our ongoing efforts in this case, IMIHGOM has performed a landscape analysis across Europe to identify late-stage clinical assets in oncology. We have leveraged our extensive network and broad knowledge in the oncology space to do so in an efficient and timely manner. We have led communication from the client side with potential partners and facilitated all stages of discussions. Based on progress to date, we expect some opportunities to move to termsheet negotiation by Q3 2018.